emerging-infectious-diseases

Documents about emerging-infectious-diseases

• Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.#900060ClinicalTrials.gov
• The IL-17A/Neutrophil axis plays a critical role in lethal infection induced by an emerging ultra-virulent <i>Streptococcus suis</i> serotype 5 strain#298372Figshare
• Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients#833817ClinicalTrials.gov
• Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses#897048ClinicalTrials.gov
• Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)#845395ClinicalTrials.gov
• An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.#623549ClinicalTrials.gov
• A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)#1032891ClinicalTrials.gov
• Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa#803048ClinicalTrials.gov
• Small Molecule Potentiator of Adjuvant Activity Enhancing Survival to Influenza Viral Challenge#675922eScholarship
• Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy#866522ClinicalTrials.gov
• Both N-Terminal and C-Terminal Histidine Residues of the Prion Protein Are Essential for Copper Coordination and Neuroprotective Self-Regulation#983427eScholarship
• Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.#982313ClinicalTrials.gov
• Pilot Implementation of HIV Self-testing Delivery in Private Pharmacies Combined to a Respondent Driven Sampling Method to Improve HIV Testing for MSM and TGW in Phnom Penh - ANRS 0100s#995561ClinicalTrials.gov
• Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis#905047ClinicalTrials.gov
• Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health#614695eScholarship
• Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3#805403ClinicalTrials.gov
• Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors#491997eScholarship
• Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers#856137ClinicalTrials.gov
• Potent CRISPR-Cas9 inhibitors from Staphylococcus genomes#620011eScholarship
• Enhanced Viral Replication and Modulated Innate Immune Responses in Infant Airway Epithelium following H1N1 Infection#970623eScholarship
• The Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients Study#996352eScholarship
• B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism#609439eScholarship
• Face masks and protection against COVID-19 and other viral respiratory infections: Assessment of benefits and harms in children#675896eScholarship
• An adaptive design to screen, treat, and retain people with opioid use disorders who use methamphetamine in methadone clinics (STAR-OM): study protocol of a clinical trial#683885eScholarship